BioXcel Therapeutics to be Acquired by Jabbok Affiliate

TL;DR

BioXcel Therapeutics is going private via acquisition by Jabbok affiliate, deal expected Q4 2025.

AI Summary

BioXcel Therapeutics, Inc. announced on August 18, 2025, that it has entered into a definitive agreement to be acquired by an affiliate of Jabbok, LLC. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions. This acquisition will result in BioXcel Therapeutics becoming a privately held company.

Why It Matters

This acquisition signifies a shift for BioXcel Therapeutics from a publicly traded entity to a private one, potentially impacting its strategic direction and access to capital.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a degree of uncertainty until the deal is finalized.

Key Players & Entities

• BioXcel Therapeutics, Inc. (company) — Registrant
• Jabbok, LLC (company) — Acquiring entity's affiliate
• August 18, 2025 (date) — Date of Report
• Fourth Quarter of 2025 (date) — Expected closing period for the acquisition

FAQ

Key Financial Figures

• $0.001 B — ch registered Common Stock, par value $0.001 BTAI The Nasdaq Capital Market Indic

Filing Documents

• tm2523368d4_8k.htm (8-K) — 31KB
• 0001104659-25-079459.txt ( ) — 193KB
• btai-20250818.xsd (EX-101.SCH) — 3KB
• btai-20250818_lab.xml (EX-101.LAB) — 33KB
• btai-20250818_pre.xml (EX-101.PRE) — 22KB
• tm2523368d4_8k_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On August 18, 2025, BioXcel Therapeutics, Inc. (the "Company") announced it had received positive pre-sNDA meeting comments from the U.S. Food and Drug Administration ("FDA") for the planned supplemental new drug application ("sNDA") submission for BXCL501 in agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting. Based on the FDA's feedback, the Company believes that the planned sNDA regulatory package will be sufficient to support the sNDA submission, which remains on track for the first quarter of 2026. The primary purpose of the planned meeting was to gain alignment with the FDA regarding the content and format of the Company's planned supplemental New Drug Application (sNDA) submission for the at-home (outpatient) use of BXCL501 for the acute treatment of agitation associated with bipolar disorders or schizophrenia, including the clinical, nonclinical, and chemistry and manufacturing and controls (CMC) requirements. The Company believes that the objectives of the pre-sNDA meeting have been accomplished based on the FDA's written responses and has determined that the meeting, originally scheduled for August 20, 2025, is no longer required. The pre-sNDA preliminary meeting comments received from FDA on August 14, 2025, will serve as the official record. Acceptance of the sNDA will be subject to the FDA's review of the complete filing.

Forward-Looking Statements

Forward-Looking Statements This current report includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this current report other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to: the Company's upcoming top-line data release for the SERENITY At-Home Phase 3 trial, the planned sNDA submission, bringing a safe and effective outpatient treatment to patients suffering from agitation and transforming the treatment paradigm. When used herein, words including "anticipate," "believe," "can," "continue," "could," "designed," "estimate," "expect," "forecast," "goal," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: its limi

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 18, 2025 BIOXCEL THERAPEUTICS, INC. /s/ Richard Steinhart By: Richard Steinhart Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR